Literature DB >> 17406160

IBS--review and what's new.

Amy Foxx-Orenstein1.   

Abstract

Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal motility disorder broadly characterized by abdominal pain/discomfort associated with altered bowel habits. The chronic and bothersome nature of IBS symptoms often negatively affects patient quality of life and activity level and places a substantial economic burden on patients and the healthcare system. Advances in research have led to a greater understanding of the underlying pathophysiology of IBS, particularly regarding the role serotonin plays in the gastrointestinal tract; the development of stepwise, symptom-based diagnostic strategies that allow for a diagnosis of IBS to be made without the need for extensive laboratory testing; and the development of treatment options targeting underlying pathophysiologic mechanisms that provide relief of the multiple symptoms associated with IBS. This review highlights recent advances in research and discusses how these findings can be applied to daily clinical practice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17406160      PMCID: PMC1781307     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  108 in total

1.  Effects of intracolonic opioid receptor agonists on polymodal pelvic nerve afferent fibers in the rat.

Authors:  X Su; V Julia; G F Gebhart
Journal:  J Neurophysiol       Date:  2000-02       Impact factor: 2.714

2.  Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits.

Authors:  J Miwa; H Echizen; K Matsueda; N Umeda
Journal:  Digestion       Date:  2001       Impact factor: 3.216

3.  Familial association in adults with functional gastrointestinal disorders.

Authors:  G R Locke; A R Zinsmeister; N J Talley; S L Fett; L J Melton
Journal:  Mayo Clin Proc       Date:  2000-09       Impact factor: 7.616

4.  Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.

Authors:  M Pimentel; E J Chow; H C Lin
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

5.  Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Authors:  M Camilleri; A R Northcutt; S Kong; G E Dukes; D McSorley; A W Mangel
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

6.  The impact of irritable bowel syndrome on health-related quality of life.

Authors:  I M Gralnek; R D Hays; A Kilbourne; B Naliboff; E A Mayer
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

7.  Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome.

Authors:  S Nobaek; M L Johansson; G Molin; S Ahrné; B Jeppsson
Journal:  Am J Gastroenterol       Date:  2000-05       Impact factor: 10.864

8.  Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome.

Authors:  R C Spiller; D Jenkins; J P Thornley; J M Hebden; T Wright; M Skinner; K R Neal
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

Review 9.  Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures.

Authors:  M Camilleri; D E Williams
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

10.  Differential effects of mu-, delta-, and kappa-opioid receptor agonists on mechanosensitive gastric vagal afferent fibers in the rat.

Authors:  N Ozaki; J N Sengupta; G F Gebhart
Journal:  J Neurophysiol       Date:  2000-04       Impact factor: 2.714

View more
  9 in total

Review 1.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Medical management of irritable bowel syndrome in 2008: current and future directions.

Authors:  Martin Storr; Christopher N Andrews
Journal:  Can J Gastroenterol       Date:  2008-08       Impact factor: 3.522

3.  Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia.

Authors:  M M Walker; N J Talley; M Prabhakar; C J Pennaneac'h; P Aro; J Ronkainen; T Storskrubb; W S Harmsen; A R Zinsmeister; L Agreus
Journal:  Aliment Pharmacol Ther       Date:  2009-01-17       Impact factor: 8.171

4.  Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis.

Authors:  Roja Rahimi; Shekoufeh Nikfar; Ali Rezaie; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2009-04-07       Impact factor: 5.742

5.  The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome.

Authors:  Shahin Merat; Shadi Khalili; Pardise Mostajabi; Anahita Ghorbani; Reza Ansari; Reza Malekzadeh
Journal:  Dig Dis Sci       Date:  2009-06-09       Impact factor: 3.199

6.  State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2008-05-07       Impact factor: 5.742

7.  Protocol for a randomized controlled study of Iyengar yoga for youth with irritable bowel syndrome.

Authors:  Subhadra Evans; Laura Cousins; Jennie C I Tsao; Beth Sternlieb; Lonnie K Zeltzer
Journal:  Trials       Date:  2011-01-18       Impact factor: 2.279

8.  The serum metabolite response to diet intervention with probiotic acidified milk in irritable bowel syndrome patients is indistinguishable from that of non-probiotic acidified milk by 1H NMR-based metabonomic analysis.

Authors:  Simon M M Pedersen; Niels Chr Nielsen; Henrik J Andersen; Johan Olsson; Magnus Simrén; Lena Ohman; Ulla Svensson; Anders Malmendal; Hanne C Bertram
Journal:  Nutrients       Date:  2010-11-23       Impact factor: 5.717

9.  Stereotaxic Exposure of the Central Nucleus of the Amygdala to Corticosterone Increases Colonic Permeability and Reduces Nerve-Mediated Active Ion Transport in Rats.

Authors:  Priya Hattay; Dawn K Prusator; Anthony C Johnson; Beverley Greenwood-Van Meerveld
Journal:  Front Neurosci       Date:  2018-08-07       Impact factor: 4.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.